GSK : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. European Stocks Are Ripe For The Picking

    February 26, 2014
    Things continue to get better for Europe. After going through some pretty nasty side-effects in the aftermath of the Great ...
  3. The United Kingdom Is Ripe For Stock Pickers

    December 6, 2013
    With the situation in Europe finally moving ahead, investors may want to focus on the United Kingdom. Stocks within the nation ...
  4. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  5. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  6. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  7. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  8. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  9. Prestige Brands Acquires Care Pharma - Analyst Blog

    July 11, 2013
    Prestige Brands Holdings, Inc. announced that it has acquired Australia-based Care Pharmaceuticals Pty Ltd.
  10. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  11. Avanir - OptiNose Collaborate - Analyst Blog

    July 3, 2013
    Avanir joined forces with OptiNose AS for the development and commercialization of AVP-825 for the treatment of acute migraine.
  12. Dr. Reddy's Launches Generic Lamictal XR - Analyst Blog

    July 1, 2013
    Dr. Reddy's announced the launch of its therapeutic equivalent generic version of Glaxo's Lamictal XR (lamotrigine) extended-release ...
  13. Teva to Acquire MicroDose Therapeutx - Analyst Blog

    June 18, 2013
    This deal is in line with Teva's strategy of strengthening its position in the respiratory therapeutic area.
  14. Orphan Drug Status for ViroPharma's Maribavir - Analyst Blog

    June 12, 2013
    ViroPharma recently received "orphan drug designation" in the EU for its pipeline candidate, maribavir, for the ...
  15. Dynavax Down on Heplisav Delay - Analyst Blog

    June 11, 2013
    Dynavax recently suffered a setback when the US Food and Drug Administration (FDA) asked for additional safety data on its ...
  16. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  17. Elan Continues To Make Baffling Strategic Decision

    May 21, 2013
    Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
  18. Another Negative Fish Oil Study Adds To Amarin's Marketing Challenges

    May 9, 2013
    More questions about the real efficacy of fish oil is bad news for Amarin.
  19. Theravance Narrows Y/Y Loss - Analyst Blog

    February 13, 2013
    Theravance Inc.'s (THRX) fourth quarter 2012 loss of 33 cents per share was narrower than the Zacks Consensus loss estimate ...
  20. AUXL Files Patent Infringement Suit - Analyst Blog

    January 31, 2013
    Auxilium Pharmaceuticals, Inc. (AUXL) recently announced the initiation of a patent infringement lawsuit against Upsher-Smith ...
  21. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  22. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  23. Generic Launch at Dr. Reddy's - Analyst Blog

    January 28, 2013
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) Singulair oral ...
  24. Launches Continue at Perrigo - Analyst Blog

    January 24, 2013
    Perrigo Company (PRGO) recently announced that it has launched over-the-counter (OTC) nicotine polacrilex mini lozenge, 2 ...
  25. CRL for Impax' Rytary - Analyst Blog

    January 23, 2013
    Impax Laboratories, Inc. (IPXL) received a major setback recently with the US Food and Drug Administration (FDA) issuing ...
  26. FDA Approves NuPathe's Zecuity - Analyst Blog

    January 18, 2013
    NuPathe, Inc. (PATH) announced that the US Food and Drug Administration (FDA) has approved Zecuity (sumatriptan iontophoretic ...
  27. Perrigo Launches Generic Luxiq Foam - Analyst Blog

    January 16, 2013
    Perrigo Company (PRGO) recently announced that it has launched betamethasone valerate foam 0.12%.  It is the generic equivalent ...
  28. Glaxo Seeks Albiglutide Approval - Analyst Blog

    January 15, 2013
    GlaxoSmithKline (GSK) recently announced the submission of a marketing application to the US Food and Drug Administration ...
  29. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  30. Glaxo/THRX Seek European Approval - Analyst Blog

    January 10, 2013
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced the submission of a marketing application to the European ...
  31. Pipeline Update from Alnylam - Analyst Blog

    January 8, 2013
    Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key "Alnylam ...
  32. Gains of 27%, 56%, and even 183%... What's Next?

    January 2, 2013
    It's every investor's dream. And this one came true... For lucky shareholders in this formerly tiny maker of automated medicine ...
  33. Glaxo's Influenza Vaccine Approved - Analyst Blog

    December 24, 2012
    GlaxoSmithKline (GSK) recently announced that it has received US Food and Drug Administration (FDA) approval for its influenza ...
  34. Stock Market News for December 20, 2012 - Market News

    December 20, 2012
    Talks between Democrats and Republicans on the Fiscal Cliff issue took a negative turn, dragging the benchmarks into the ...
  35. CHMP Negative on Isis' Kynamro - Analyst Blog

    December 17, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend ...
  36. Isis Pharma, AstraZeneca Ink Deal - Analyst Blog

    December 14, 2012
    Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover ...
  37. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  38. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  39. Glaxo Invests in Nigeria - Analyst Blog

    November 28, 2012
    GlaxoSmithKline (GSK) recently announced that it has reached an agreement with GlaxoSmithKline Consumer Nigeria plc regarding ...
  40. Glaxo to Expand in India - Analyst Blog

    November 27, 2012
    GlaxoSmithKline (GSK) recently announced its decision to increase its holding in its consumer healthcare subsidiary in India ...
  41. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
  42. Another Generic from Dr. Reddy's - Analyst Blog

    November 23, 2012
    Dr. Reddy's Laboratories (RDY) recently launched its generic version of Pfizer's (PFE) pulmonary arterial hypertension (PAH) ...
  43. Glaxo's Promacta Label Expanded - Analyst Blog

    November 20, 2012
    GlaxoSmithKline (GSK) recently announced that the US Food and Drug Administration (FDA) has approved an additional indication ...
  44. Weak Quarter from Auxilium Pharma - Analyst Blog

    November 8, 2012
    Auxilium Pharmaceuticals, Inc. (AUXL) reported a loss of 21 cents per share in the third quarter of 2012, wider than the ...
  45. Isis Misses on Both Counts - Analyst Blog

    November 7, 2012
    Isis Pharmaceuticals Inc. (ISIS) reported a adjusted net loss of 33 cents per share in the third quarter of 2012, wider than ...
  46. Revenues Decline at Alnylam - Analyst Blog

    November 7, 2012
    Alnylam Pharmaceuticals Inc.'s (ALNY) third quarter 2012 net loss of 38 cents per share was wider than the year-ago loss ...
  47. Loss at THRX Narrower Than Expected - Analyst Blog

    October 31, 2012
    Theravance Inc.'s (THRX) third quarter 2012 loss of 37 cents per share was narrower than the Zacks Consensus loss Estimate ...
  48. Theravance, Merck Ink Deal - Analyst Blog

    October 18, 2012
    Theravance Inc. (THRX) recently announced that it has inked a deal with Merck (MRK) for the discovery, development and commercialization ...
  49. Isis Pharma Owns 18% of Regulus - Analyst Blog

    October 12, 2012
    Isis Pharmaceuticals, Inc. (ISIS) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics ...
  50. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  51. Roche Oncology Candidate Progresses - Analyst Blog

    October 2, 2012
    Roche Holdings Ltd. (RHHBY) recently announced additional results from its phase III EMILIA study, which was conducted with ...
  52. Dr. Reddy's Launches Generic Amoxil - Analyst Blog

    September 21, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of GlaxoSmithKline's (GSK) Amoxil (amoxicillin) ...
  53. Glaxo Aims to Expand Synflorix Label - Analyst Blog

    September 19, 2012
    GlaxoSmithKline plc (GSK) recently announced that it is seeking to expand the label of Synflorix in EU and has submitted ...
  54. Glaxo Increases Stake in RGDX - Analyst Blog

    September 18, 2012
    GlaxoSmithKline (GSK) recently announced it has hiked its stake in Response Genetics Inc. (RGDX), a company focused on the ...
  55. Neutral on Auxilium Pharma - Analyst Blog

    September 18, 2012
    We recently reiterated our Neutral recommendation on Auxilium Pharmaceuticals, Inc. (AUXL) which carries a Zacks #3 Rank ...
  56. Abbott-Astellas Collaborate - Analyst Blog

    September 13, 2012
    Abbott Laboratories (ABT) recently announced that it is collaborating with Astellas Pharma Global Development for a phase ...
  57. Dr. Reddy's Launches Generic Toprol - Analyst Blog

    September 12, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca's (AZN) hypertension drug ...
  58. Positive Results on Roche Candidate - Analyst Blog

    August 27, 2012
    Roche Holdings Ltd. (RHHBY) recently announced results from its phase III study (EMILIA study) of trastuzumab emtansine (T-DM1). ...
  59. Pipeline Advances at Glaxo/THRX - Analyst Blog

    August 27, 2012
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced that they have completed the phase III program for their ...
  60. Alnylam/Isis's Regulus to Go Public - Analyst Blog

    August 22, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  61. Isis Loss Down on Higher Revenues - Analyst Blog

    August 9, 2012
    Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 1 cent per share in the second quarter of 2012, well below the year-ago ...
  62. Alnylam Earns Milestone Payment - Analyst Blog

    August 6, 2012
    Alnylam Pharmaceuticals Inc. (ALNY) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK). ...
  63. A Profitable Quarter for Auxilium - Analyst Blog

    August 2, 2012
    Auxilium Pharmaceuticals, Inc. (AUXL) swung to a profit in the second quarter of 2012 with earnings coming in at 16 cents ...
  64. Pipeline Progresses at Nymox - Analyst Blog

    July 12, 2012
    Nymox Pharmaceutical Corporation (NYMX) recently announced that it has completed enrollment of benign prostatic hyperplasia ...
  65. Glaxo Reports Data on Diabetes Drug - Analyst Blog

    July 12, 2012
    GlaxoSmithKline (GSK) recently announced positive results from the Harmony 6 phase III study, evaluating the use of albiglutide ...
  66. Positive Data on Theravance Drug - Analyst Blog

    July 11, 2012
    Theravance Inc. (THRX) recently announced positive top-line results on TD-1211 from a phase IIb study, 0084. TD-1211 is an ...
  67. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  68. The Week Ahead In Healthcare

    July 6, 2012
    Early July offers another slow week in healthcare.
  69. Positive Data on Glaxo & THRX Drug - Analyst Blog

    July 3, 2012
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced data from four pivotal phase III studies conducted with ...
  70. Healthcare Outlook For The Week Ahead

    July 3, 2012
    Looking at news that may move healthcare stocks during this week.
  71. FDA Nod for Perrigo Generic - Analyst Blog

    June 29, 2012
    Perrigo Co. (PRGO) recently announced that it had received US Food and Drug Administration (FDA) approval for its abbreviated ...
  72. UK's Global Footprint Stocks

    June 27, 2012
    Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
  73. New Lease Agreements for Alexandria - Analyst Blog

    June 8, 2012
    Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements ...
  74. Ahead of Wall Street - May 9, 2012 - Ahead of Wall Street

    May 9, 2012
    Wednesday, May 9, 2012 It's all about Greece. Today's trading action may not be as volatile as the one on Tuesday, but ...
  75. Truly a World-Class Fund

    April 26, 2012
    There’s no one place for growth any longer, so it pays to diversify across world markets and few funds do it better ...
  76. 3 Biotechs on the Verge

    April 11, 2012
    The risks are huge, but well worth the potential rewards, writes MoneyShow.com senior editor Igor Greenwald. Let’s ...
  77. The Perfect Rx for Your Portfolio

    April 4, 2012
    These three big drug stocks offer attractive yields and relative safety heading into the more challenging summer months, ...
  78. Diversified Investment Appeal From Novartis

    January 27, 2012
    The healthcare giant reported impressive results in 2011 and offers a reasonable valuation and solid dividends.
  79. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  80. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  81. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  82. Despite Inflation Woes India Outshines In Asia

    September 23, 2011
    Despite its inflationary pressures, India's strength and investment potential continues to grow.
  83. Vivus Tries A New Path

    September 21, 2011
    Vivus takes a more pragmatic approach to getting Qnexa to market.
  84. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  85. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  86. Vical Gets Some Validation

    July 19, 2011
    Vical gets a small victory with a partnership for its CMV drug.
  87. Transcept Pharmaceuticals Bulls Get Rude Awakening

    July 15, 2011
    Transcept gets a major setback, but it may not be doomed.
  88. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  89. Dividends To Avoid

    May 4, 2011
    A company that offers dividends isn't always a safe long-term bet. Find out which dividend-issuing companies you should avoid.
  90. Lilly Will Pay Investors For Patience

    April 20, 2011
    Lilly isn't dynamic, but the value is there.
  91. Amarin's Magic Pill

    April 19, 2011
    Strong clinical data sends Amarin's stock soaring.
  92. Approval In Hand, Does Xenoport Have The Legs To Run?

    April 11, 2011
    Xenoport's pipeline is thin, but Horizant approval buys valuable time.
  93. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  94. Salix Proves There Is Still Growth In Pharma

    March 3, 2011
    Salix has taken another blow from the FDA, but seems too cheap given its prospects.
  95. Novavax Gets A Booster Shot From The Government

    March 1, 2011
    Novavax gets a sizable contract from the government that will largely fund its remaining clinical trials for flu vaccines.
  96. UK's Global Footprint Stocks

    January 27, 2011
    Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
  97. Hi-Tech Pharmacal Has A Nose For Profits

    January 26, 2011
    Hi-Tech Pharmacal is a micro-cap generic drug manufacturer that has had very solid profits in recent months.
  98. U.K. A Value Bet Amid Euro Debt Crisis

    January 20, 2011
    The ongoing financial crisis in the European Union has made the United Kingdom a promising prospect for value investors. ...
  99. Forest Labs Has Wood To Chop

    January 19, 2011
    Will Forest be able to plug a gaping hole in its future revenue?
  100. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  101. Can New Leadership Rejuvenate Big Pharma?

    December 8, 2010
    Will another new drug company CEO make a difference in a stagnating industry?
  102. Human Genome Takes A Big Step Forward

    November 17, 2010
    HGSI's prospects get a big boost from a panel approval.
  103. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact does it ...
  104. The Rest Of The Disappointing Story

    July 23, 2010
    There's more to the story than one lousy quarter for PetMed Express and Gilead.
  105. Cancer Vaccines Continue To Show Promise

    July 7, 2010
    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  106. What Ails Amgen?

    June 30, 2010
    Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
  107. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
  108. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
  109. Amgen's New Double-Play Drug

    June 8, 2010
    Amgen hopes for a boost in revenue from their just-approved multi-purpose drug, Prolia.
  110. Big Pharma's On Sale

    June 4, 2010
    Stocks of some of the large pharmaceutical companies are now available at attractive prices.
  111. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  112. WellPoint Still On Point

    April 30, 2010
    Amid all of the furor over healthcare reform, WellPoint leveraged a tough environment into another strong quarter.
  113. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  114. Fighting The Unstable European Union

    March 3, 2010
    Protection is the name of the game, and these options can help shield you from a volatile European Union.
  115. UK's Global Footprint Stocks

    January 13, 2010
    Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
  116. H1N1 Vaccines Finally Bearing Revenue

    December 9, 2009
    Investors lost interest in swine flu vaccine stocks, like AZN and GSK, before they had a chance to enjoy any revenue.
  117. McKesson Riding High On H1N1

    October 29, 2009
    Investors should keep a close watch on drug distribution firm McKesson's stock.
  118. Long-Term Flu Plays

    October 2, 2009
    Flu vaccine shares still have long-term appeal.
  119. Merck Regaining Its Swagger

    August 25, 2009
    Merck regaining its swagger, after a steady decline last year.
  120. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  121. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  122. Big Pharma's Buying Spree

    April 24, 2009
    A look at recent merger and acquisition activity in the pharmaceutical sector and possible opportunities if the trend continues.
  123. Abbott Labs A Solid Pharma Stock

    April 3, 2009
    Abbott Labs has continued to perform solidly as a business and looks poised with its product line to keep going strong.
  124. Dividend Darlings Or Dividend Disappointments?

    March 26, 2009
    Even with declining sales, Whirlpool has the stock prices and dividend yields that make it a company of interest.
  125. Betting On Job Losses

    February 5, 2009
    The current job losses aren't pretty. As investors, we have ways to play this.
  126. Big Predictions For Big Pharma

    January 2, 2009
    As defensive plays, Big Pharma stocks could beat the economic crunch.
  127. Sigma-Aldrich's New Tech Proves Recession-Proof

    October 29, 2008
    Sigma-Aldrich's Q3 earnings were steady, and with downside protection a major theme in the markets these days, it's hard ...
  128. Alcon Takes A Poke In The Eye

    October 28, 2008
    Despite investor worries over Alcon's growth, the eye care company is a proven winner.
  129. Pfizer Drug Development Ahead Of Schedule

    October 6, 2008
    Pfizer's late-stage drug pipeline has gone from 16 to 25 drugs in six months, and a high dividend cushions returns while ...
  130. The Contrarian Case For Pfizer

    August 29, 2008
    Pfizer has plenty of free cash for R&D or acquisitions, and its low forward P/E provides a solid margin of safety.
  131. Pfizer: What's In Your Pipeline?

    April 29, 2008
    If your looking to add value to your portfolio consider Pfizer for its sound fundamentals and enticing dividend.
  132. Abbott Labs Finally Turns Potential Into Profit

    April 17, 2008
    Solid numbers for the last two quarters could change Abbott Labs's reputation as an overvalued stock.
  133. U.S. Cancer Vaccine Gets The Green Light - In Russia

    April 11, 2008
    Russia approved U.S. biotech Antigenics' kidney cancer vaccine. The dawn of a potentially lucrative market may be at hand.
  134. Novartis' Eye-Catching Deal Won't Add Value

    April 8, 2008
    Novartis is spreading itself too thin with yet another acquisition - this time for vision specialist Alcon.
  135. Small Caps For Big Cures (VRTX, VRX, MLNM)

    July 27, 2007
    These three companies are on the cutting edge, but can they carve out big returns for investors?
  136. Pharming it Out (WYE, GSK, MRK)

    April 13, 2007
    The big pharma stocks are still in the midst of battle, and investors need to take heed.
  137. You Gotta Know When To Bail

    February 22, 2007
    When your stock's prospects take a turn for the worse, bailing out can be the best possible option.
  138. Winners and Losers - November 27th - December 1st (DVAX, DBRN, ...

    December 1, 2006
    A look at some of the market's winners and losers for the week of November 27th.
  139. Winners and Losers - September 4th - 8th (SYX, BNP, EFX, ADLR, ...

    September 8, 2006
    A look at the winners and losers for the week of September 4th.
  140. Merck's Worth A Look (MRK)

    August 14, 2006
    Despite Merck's foibles, a cure could be on the way.
  141. Pfizer, Pass the Rolaids

    June 12, 2006
    $15 billion for its consumer products unit won’t cure Pfizer’s ailing stock.
  142. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center